z-logo
Premium
Checkpoint inhibitors in H odgkin's lymphoma
Author(s) -
Jezeršek Novaković Barbara
Publication year - 2016
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12697
Subject(s) - pembrolizumab , nivolumab , immune system , lymphoma , cancer research , blockade , antibody , immune checkpoint , population , priming (agriculture) , immunology , medicine , immunotherapy , biology , receptor , botany , environmental health , germination
Abstract H odgkin's lymphoma is unusual among cancers in that it consists of a small number of malignant H odgkin/ R eed– S ternberg cells in a sea of immune system cells, including T cells. Most of these T cells are reversibly inactivated in different ways and their reactivation may induce a very strong immune response to cancer cells. One way of reactivation of T cells is with antibodies blocking the CTLA ‐4 and especially with antibodies directed against PD ‐1 or the PD ‐ L 1 ligand thereby reversing the tumor‐induced downregulation of T ‐cell function and augmenting antitumor immune activity at the priming ( CTLA ‐4) or tissue effector ( PD ‐1) phase. Immune checkpoint inhibitors have been evidenced as an additional treatment option with substantial effectiveness and acceptable toxicity in heavily pretreated patients with H odgkin's lymphoma. Particularly, PD ‐1 blockade with nivolumab and pembrolizumab has demonstrated significant single‐agent activity in this select population.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here